5-methyl-4,5,6,7-tetrahydrofuro<3,2-c>pyridine | 76312-02-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 5-methyl-4,5,6,7-tetrahydrofuro<3,2-c>pyridine
• 英文别名: 5-Methyl-4,5,6,7-tetrahydrofuro[3,2-c]pyridine；5-methyl-6,7-dihydro-4H-furo[3,2-c]pyridine
• CAS: 76312-02-2
• 化学式: C₈H₁₁NO
• 分子量: 137.181
• InChiKey: JATVVDJYJXMVQE-UHFFFAOYSA-N

物化性质

• 沸点：
  184.9±30.0 °C(Predicted)
• 密度：
  1.054±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  16.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-methyl-4,5,6,7-tetrahydrofuro<3,2-c>pyridine 、 碘甲烷 以 乙醚 为溶剂， 反应 10.0h， 以80%的产率得到5,5-Dimethyl-4,5,6,7-tetrahydrofuro<3,2-c>pyridiniumiodid
  参考文献：
  名称：

  Dihydroisochinolinumlagerung, 30. Mitt. Synthese einiger Furo[3,2-c]pyridine

  摘要：

  DOI：

  10.1002/ardp.19803130916
• 作为产物：
  描述：

  4,5-二氢-4-氧代呋喃[3,2]吡啶 在 lithium aluminium tetrahydride 、 三溴化磷 作用下， 以 乙醇 为溶剂， 反应 8.0h， 生成 5-methyl-4,5,6,7-tetrahydrofuro<3,2-c>pyridine
  参考文献：
  名称：

  Dihydroisochinolinumlagerung, 29. Mitt. 4-Benzyl-5-methyl-4,5-dihydrofuro[3,2-c]pyridine

  摘要：

  AbstractDie Synthese von 4‐Benzyl‐5‐methyl‐4,5‐dihydrofuro[3,2‐c]pyridin (7) wird beschrieben. 7 ergibt mit verdünnten Säuren nicht die erwartete Umlagerung, und es kann kein definiertes Reaktionsprodukt isoliert werden. Auch die Einführung einer Methylgruppe in 2‐Stellung, die zu 14 führt, vermag das Furopyridinenamin nicht zu stabilisieren. Die Tetrahydroverbindung 10 ist dagegen unter den Umlagerungsbedingungen stabil.

  DOI：

  10.1002/ardp.19813140211

文献信息

• 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE
  申请人：Horiuchi Yoshihiro

  公开号：US20120225876A1

  公开（公告）日：2012-09-06

  Disclosed is a compound represented by formula (1) or a pharmacologically acceptable salt thereof (In the formula, A represents a group that is represented by formula (A-1); R 1a and R 1b may be the same or different and each independently represents a C 1-6 alkyl group which may be substituted by one to three halogen atoms; m and n each independently represents an integer of 0-5; X 1 represents a hydroxyl group or an aminocarbonyl group; Z 1 represents a single bond or the like; and R 2 represents an optionally substituted C 1-6 alkyl group, an optionally substituted C 6-10 aryl group or the like.)

  公开了一种由公式(1)表示的化合物或其药理可接受的盐(在公式中，A代表由公式(A-1)表示的基团；R1a和R1b可以相同或不同，每个独立地表示一个可以由一个到三个卤素原子取代的C1-6烷基；m和n各自独立地表示0-5之间的整数；X1代表羟基或氨基甲酰基；Z1代表单键等；R2代表一个可选地取代的C1-6烷基，一个可选地取代的C6-10芳基等)。
• BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
  申请人：Katayama Seiji

  公开号：US20130116227A1

  公开（公告）日：2013-05-09

  Disclosed is a novel biaryl amide derivative represented by formula (1) and having an affinity for the aldosterone receptor; also disclosed is a pharmaceutically acceptable salt thereof. (In the formula, A is any of the groups represented by formula (a); L is —CONH—, etc.; R 1 is a substitutable aminosulfonyl group, etc.; R 2 is a hydrogen atom, etc.; R 3 is a hydrogen atom, etc.; R 4 is a hydrogen atom, a halogen atom, hydroxy group, a substitutable amino group, a substitutable C 1-6 alkoxy group, a substitutable 4- to 7-membered cyclic amino group, etc.; R 5a , R 5b and R 5c are each independently hydrogen atoms, etc.; R 6 is a halogen atom, a cyano group, etc.; R 7 and R 8 are each independently a hydrogen atom, etc.; and m is an integer such as 0.)

  揭示了一种表示为公式（1）的新型联苯酰胺衍生物，具有与醛固酮受体的亲和力；还揭示了其药用可接受的盐。（在该公式中，A是由公式（a）表示的任何基团之一；L是—CONH—等；R1是可替代的氨基磺酰基等；R2是氢原子等；R3是氢原子等；R4是氢原子、卤原子、羟基、可替代的氨基基团、可替代的C1-6烷氧基、可替代的4-到7-成员环氨基基团等；R5a、R5b和R5c各自独立地是氢原子等；R6是卤原子、氰基等；R7和R8各自独立地是氢原子等；m是整数，例如0。）
• [EN] 3-SUBSTITUTED CARBONYL-NAPHTHO[2,3-B]FURANE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF<br/>[FR] DÉRIVÉ DE CARBONYLE -NAPHTO [2,3-B]FURANE 3-SUBSTITUÉ DÉRIVÉ OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI
  申请人：BOSTON BIOMEDICAL INC

  公开号：WO2015120304A1

  公开（公告）日：2015-08-13

  The present invention provides a compound of the following Formula (1) or a pharmaceutically acceptable salt thereof: Formule (i) wherein X is an oxygen atom and the like; Y is -CO-, -S02-and the like; R1 is an optionally- substituted C1-6 alkyl group, an optionally-substituted C1-6 alkylcarbonyl group and the like; R2 is an optionally- substituted C1-6 alkyl group, an optionally-substituted C1-6 alkoxy group, an optionally-substituted amino group, an optionally-substituted 5- to 12-membered monocyclic or polycyclic saturated heterocyclic group and the like; R3, R4, R5, and R6 are independently a hydrogen atom and the like which exhibits excellent effects in suppressing the proliferation and sphere-forming ability of cancer cells, and can be useful as an antitumor drug or cell growth inhibitor.

  本发明提供以下式（1）的化合物或其药学上可接受的盐：式（i）其中X是氧原子等；Y是-CO-，-S02-等；R1是可选择地取代的C1-6烷基，可选择地取代的C1-6烷基羰基等；R2是可选择地取代的C1-6烷基，可选择地取代的C1-6烷氧基，可选择地取代的氨基，可选择地取代的5-至12-成员的单环或多环饱和杂环基等；R3、R4、R5和R6独立地是氢原子等，对抑制癌细胞的增殖和球形形成能力具有出色效果，并可用作抗肿瘤药物或细胞生长抑制剂。
• NEW TRICYCLIC QUINONE DERIVATIVE
  申请人：Boston Biomedical, Inc

  公开号：US20170015677A1

  公开（公告）日：2017-01-19

  This invention provides a compound represented by formula (1) or a pharmaceutically acceptable salt thereof. Specifically, the present invention provides a compound represented by formula (1) or a pharmaceutically acceptable salt thereof [Therein, A is O, S, or N—R 6 ; ring G is a 5-membered or 6-membered aromatic ring, etc., including 1-3 heteroatoms selected from O, S and N as constituent atoms; R 1 and R 2 are each independently a hydrogen atom, a halogen atom, or an optionally-substituted C 1-6 alkyl carbonyl group, etc.; R 3 , R 4 and R 5 are each independently a hydrogen atom, a halogen atom, or an optionally-substituted C 1-6 alkyl carbonyl group, etc.; and R 6 is a hydrogen atom or an optionally-substituted C 1-6 alkyl group, etc.].

  这项发明提供了由式（1）表示的化合物或其药学上可接受的盐。具体来说，本发明提供了由式（1）表示的化合物或其药学上可接受的盐【其中，A为O、S或N—R6；环G为5-元环或6-元芳香环等，包括1-3个选自O、S和N的杂原子作为成分原子；R1和R2各自独立地是氢原子、卤素原子或一个可选择取代的C1-6烷基羰基基团等；R3、R4和R5各自独立地是氢原子、卤素原子或一个可选择取代的C1-6烷基羰基基团等；R6是一个氢原子或一个可选择取代的C1-6烷基基团等】。
• [EN] N-ACYL CYCLIC AMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF<br/>[FR] DÉRIVÉ D'AMINE N-ACYLE CYCLIQUE OU SON SEL PHARMACEUTIQUEMENT ACCEPTABLE
  申请人：DAINIPPON SUMITOMO PHARMA CO

  公开号：WO2011111875A1

  公开（公告）日：2011-09-15

  The present invention provides compounds which show high effectiveness against positive symptoms, negative symptoms and cognitive dysfunction in schizophrenia and reduce conventional side-effect risks as well as have remarkable effects for central neurological diseases associated with cognitive dysfunction other than schizophrenia. N-Acyl cyclic amine derivatives of formula (1): wherein Ar1 and Ar2 are aryl or heteroaryl; V is nitrogen, or CR3; W1 is a single bond, -C(O)-, etc.; W2 is C1- alkylene; W3 is a single bond, methylene, -NH-, -CR4=CR5-, etc.; Ring Q is a group of formula (a) in which n is 0 or 1; m is 0 to 2; k is 1 to 3; Z is a single bond, methylene, oxygen, etc.; R1a, R1b and R1c are each, same or different, hydrogen, hydroxyl, halogen, cyano, C1-6 alkyl, etc.; or pharmaceutically acceptable salts thereof are provided.

  本发明提供了一种化合物，对于精神分裂症的阳性症状、阴性症状和认知功能障碍具有高效性，同时减少了传统的副作用风险，并对与精神分裂症以外的认知功能障碍相关的中枢神经系统疾病具有显著效果。提供了式（1）的N-酰基环胺衍生物，其中Ar1和Ar2是芳基或杂环芳基；V是氮或CR3；W1是单键，-C(O)-等；W2是C1-烷基；W3是单键，亚甲基，-NH-，-CR4=CR5-等；环Q是式（a）的一组，其中n为0或1；m为0到2；k为1到3；Z是单键，亚甲基，氧等；R1a、R1b和R1c分别是相同或不同的氢、羟基、卤素、氰基、C1-6烷基等；或其药用可接受盐。